compname reports q2 earnings per share $6.05.
sees fy adjusted earnings per share $26 to $28.
q3 adjusted earnings per share $6.82.
qtrly revenue rose 4.3 percent to $4.1 billion.
sees fy sales up 18.5% to 19.5%.
sees 2021 revenue growth in diagnostics by 8% to 10%.
sees fy 2021 base business growth of 21.5% to 22.5%.
qtrly average 114,000 tests per day, compared with 115,000 per day in q2 of 2020.
sees fy adjusted earnings per share to be about 25%.
q3 adjusted earnings per share $6.82 excluding items.
qtrly pcr testing volume averaged 85,000 per day, up from 54,000 in q2.
qtrly core business for both diagnostics and drug development grew 10% and 22%.
qtrly revenue rose 17.5 percent to $1.5 billion.
qtrly adjusted operating income of $907 million, or 22.3 percent, excluding items.
qtrly organic revenue increased 3.4 percent to $3.4 billion.
qtrly operating income of $767 million, or 18.9% of revenue.
